Study wrapper · #876
Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: A Target Trial Emulation.
Lipska KJ, Zawack K, Yan L, et al. Annals of internal medicine. 2026.
DOI: 10.7326/annals-25-05216PubMed: 42441965
Editor's note
A well-designed target-trial emulation finding no advantage for GLP-1RAs over SGLT-2i or DPP-4i for insulin discontinuation in type 2 diabetes. Semaglutide made up most of the GLP-1RA arm but was not analyzed separately, and the cohort was overwhelmingly older male veterans, limiting generalizability. This tempers expectations that GLP-1RAs help patients come off insulin, a useful counterweight to the enthusiasm around this class.
Plain-language abstract
In a large study emulating a trial using Veterans Health records, adding a GLP-1 receptor agonist (mostly semaglutide) to basal insulin did not make patients more likely to stop insulin than two other add-on drug classes. The finding held across subgroups.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026